Eli Lilly and Company (NYSE:LLY) Shares Acquired by Arbor Trust Wealth Advisors LLC

Arbor Trust Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,271 shares of the company’s stock after purchasing an additional 90 shares during the period. Arbor Trust Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $741,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in LLY. Fairfield Bush & CO. purchased a new stake in shares of Eli Lilly and Company during the first quarter valued at $107,000. Roundview Capital LLC grew its holdings in shares of Eli Lilly and Company by 2.6% during the first quarter. Roundview Capital LLC now owns 2,056 shares of the company’s stock valued at $589,000 after buying an additional 53 shares during the last quarter. Merit Financial Group LLC purchased a new stake in Eli Lilly and Company in the first quarter valued at $210,000. NewEdge Advisors LLC boosted its holdings in Eli Lilly and Company by 9.9% in the first quarter. NewEdge Advisors LLC now owns 53,052 shares of the company’s stock valued at $15,193,000 after purchasing an additional 4,774 shares during the last quarter. Finally, Barometer Capital Management Inc. purchased a new stake in Eli Lilly and Company in the first quarter valued at $561,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the firm’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on LLY shares. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Truist Financial reaffirmed a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, Bank of America increased their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Price Performance

LLY stock traded down $4.21 during mid-day trading on Tuesday, reaching $746.56. The company’s stock had a trading volume of 2,569,130 shares, compared to its average volume of 3,085,273. The company’s 50 day moving average is $762.68 and its two-hundred day moving average is $655.54. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The stock has a market cap of $709.35 billion, a PE ratio of 128.34, a P/E/G ratio of 1.65 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter last year, the company posted $2.09 EPS. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. Equities research analysts expect that Eli Lilly and Company will post 12.46 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.